KEI Comments to USTR regarding 2018 Special 301 list
Author: James Love
PhRMA letter on Colombia Resolution 5246
On January 15, 2018, PhRMA provided comments on the Colombian Resolution 5246, a public interest declaration for several drugs for the hepatitis c virus (HCV). A copy of the PhRMA letter is attached below. It is a combination of complaints… Continue Reading
NIH wants to give Gilead a new, government subsidized monopoly on CAR T technology, this one for CD-30 proteins.
2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology
Contact: Kim Treanor 202-332-2670; kim.treanor@keionline.org January 5, 2018 The National Institutes of Health (NIH) has proposed an exclusive license with Gilead for certain patent applications for inventions that target CD-30 proteins and CAR T technologies. The proposed license is to… Continue Reading
Senate tax bill will not make orphan drug tax credits transparent as to company, drug and disease
In a reversal from the version that passed out of the Senate Finance Committee, the version of the tax bill that passed the Senate eliminated the requirement that the Orphan Drug tax credit be transparent as to taxpayer, drug and… Continue Reading
Civil Society joint position at 1st World Conference on Access to Medicine
Attached is the Civil Society input to the 1st World Conference on Access to Medical Products and International Laws for Trade and Health in the context of the 2030 Agenda for Sustainable Development that took place in Delhi, India in… Continue Reading
Senate proposes to cut Orphan Drug Tax Credit to 27.5 percent, and make it public
The Managers Amendment for the “Tax Cuts and Jobs Act” is available on the Senate Finance web page here: https://www.finance.senate.gov/imo/media/doc/11.20.17%20Tax%20Cuts%20and%20Jobs%20Act.pdf or here: 11.20.17 Tax Cuts and Jobs Act I was looking over the Orphan Drug Tax Credit (ODTC) language. The… Continue Reading
KEI comments in FDA-2017-N-3615
On November 17, 2017, KEI provided comments in KEI-FDA-2017-N-3615 These were the topics discussed: Transparency Clinical trial costs Data from the Orphan Drug program Costs of trials for government funded research Asset acquisition costs. Licensing Access to Knowhow, data and materials… Continue Reading
KEI Presentation at World Conference on Access to Medicines, New Dehli
From November 21 to 23, the Government of India and the World Health Organization are hosting the “1st World Conference on Access to Medical Products and International Laws for Trade and Health, in the Context of the 2030 Agenda for… Continue Reading
Fred Hutchinson Cancer Center often fails to disclose federal funding of inventions on initial patent
Summary:
- A review of the “certificate of correction” to patents assigned to the Fred Hutchinson Cancer Center finds frequent failures to disclose federal funding on initial patent applications.
- When Fred Hutchinson reported no federal funding on patent applications, it was wrong 45 percent of the time, according to corrections later filed with the USPTO.
On October 19, 2017, I ran a query of the USPTO database of granted patents to identify patents granted to the Seattle based Fred Hutchinson Cancer Center.